Biliary Tract Cancer

Oncology·MeSH: Biliary Tract Neoplasms

Prevalence

4.2 / 100K

Incidence

3.0 / 100K/yr

16 drugs in development·11 companies·22 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
ziihera	Zymeworks Inc. (ZYME)

Phase 3(7)

Drug	Company
cardonilizumab	Merus N.V. (MRUS)
Leucovorin	ENANTA PHARMACEUTICALS INC (ENTA)
Leucovorin calcium/Levoleucovorin	ENANTA PHARMACEUTICALS INC (ENTA)
Nanvuranlat	IGM Biosciences, Inc. (IGMS)
s-1 [tegafur/oteracil/gimeracil]	ASTRAZENECA PLC (AZN)
tovecimig	Compass Therapeutics, Inc. (CMPX)
Zanidatamab	Jazz Pharmaceuticals plc (JAZZ)

Phase 2(6)

Drug	Company
Binimetinib	Merus N.V. (MRUS)
incb001158	Incyte Corp. (INCY)
leucovorin	Incyte Corp. (INCY)
Leucovorin	Jazz Pharmaceuticals plc (JAZZ)
NALIRI	KYNTRA BIO INC. (KYNB)
ts-1	GH Research PLC (GHRS)

Phase 1(1)

Drug	Company
LM-302	Merus N.V. (MRUS)

Unknown(1)

Drug	Company
First-Line Systemic Therapy	Tango Therapeutics, Inc. (TNGX)

BioSniper tracks 16 drugs in development for Biliary Tract Cancer across 11 companies.

There are 22 clinical trials targeting Biliary Tract Cancer tracked by BioSniper.

The estimated prevalence of Biliary Tract Cancer is approximately 4.2 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.